Sage Therapeutics has suffered another disappointment after deciding that it will have to drop the Parkinson’s programme for key pipeline drug dalzanemdor after it showed
Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of
Sage Therapeutics is facing the possibility of job losses and other cutbacks in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the
Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a requ
Shares in Praxis Precision Medicines were in freefall today after the company's efforts to develop a new therapy for major depressive disorder (MDD) ended in failure, forcing a restructurin
Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response.
AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.